[go: up one dir, main page]

CY1119843T1 - Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης - Google Patents

Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης

Info

Publication number
CY1119843T1
CY1119843T1 CY20171101334T CY171101334T CY1119843T1 CY 1119843 T1 CY1119843 T1 CY 1119843T1 CY 20171101334 T CY20171101334 T CY 20171101334T CY 171101334 T CY171101334 T CY 171101334T CY 1119843 T1 CY1119843 T1 CY 1119843T1
Authority
CY
Cyprus
Prior art keywords
ornithine
phynyloxin
production methods
methods
forms
Prior art date
Application number
CY20171101334T
Other languages
English (en)
Inventor
Keith Anderson
Jim Behling
Christine Henderson Dougan
Stephen William Watt
Peter Manini
Attilia Figini
Original Assignee
Ocera Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics, Inc. filed Critical Ocera Therapeutics, Inc.
Publication of CY1119843T1 publication Critical patent/CY1119843T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Αποκαλύπτονται στο παρόν κρυσταλλικές μορφές φαινυλοξικής L-ορνιθίνης και μέθοδοι παρασκευής αυτών. Η κρυσταλλική μορφή μπορεί, σε κάποιες υλοποιήσεις, να είναι οι Μορφές I, II, III και V ή μείγματα αυτών. Οι κρυσταλλικές μορφές μπορούν να μορφοποιηθούν για τη θεραπεία υποκειμένων με ηπατικές διαταραχές, όπως ηπατική εγκεφαλοπάθεια. Επομένως, κάποιες υλοποιήσεις περιλαμβάνουν σκευάσματα και μεθόδους χορήγησης της φαινυλοξικής L-ορνιθίνης.
CY20171101334T 2009-04-03 2017-12-20 Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης CY1119843T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16667609P 2009-04-03 2009-04-03
PCT/US2010/029708 WO2010115055A1 (en) 2009-04-03 2010-04-01 L-ornithine phenyl acetate and methods of making thereof

Publications (1)

Publication Number Publication Date
CY1119843T1 true CY1119843T1 (el) 2018-06-27

Family

ID=42828717

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101334T CY1119843T1 (el) 2009-04-03 2017-12-20 Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης

Country Status (26)

Country Link
US (9) US8173706B2 (el)
EP (4) EP2413924B1 (el)
JP (6) JP6144488B2 (el)
KR (6) KR20220067001A (el)
CN (3) CN106810464B (el)
AU (1) AU2010232521B2 (el)
BR (1) BRPI1013657A2 (el)
CA (5) CA2998344C (el)
CY (1) CY1119843T1 (el)
DK (3) DK3686183T3 (el)
EA (2) EA023051B1 (el)
ES (3) ES2791524T3 (el)
HR (2) HRP20221232T8 (el)
HU (2) HUE060371T2 (el)
IL (2) IL215449B (el)
LT (2) LT2413924T (el)
MX (4) MX388894B (el)
NO (1) NO2413924T3 (el)
NZ (3) NZ595706A (el)
PL (2) PL2413924T3 (el)
PT (2) PT3686183T (el)
SG (3) SG10202010988WA (el)
SI (1) SI2413924T1 (el)
SM (2) SMT202200395T1 (el)
WO (1) WO2010115055A1 (el)
ZA (1) ZA201107189B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG158073A1 (en) 2004-11-26 2010-01-29 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
LT2413924T (lt) * 2009-04-03 2018-02-12 Ocera Therapeutics, Inc. L-ornitino fenilo acetatas ir jo gavimo būdai
MX375116B (es) 2009-06-08 2025-03-06 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
US8068011B1 (en) 2010-08-27 2011-11-29 Q Street, LLC System and method for interactive user-directed interfacing between handheld devices and RFID media
MX360062B (es) 2010-10-06 2018-10-22 Ocera Therapeutics Inc Metodos de elaboracion de fenilacetato de l-ornitina.
CN102993037B (zh) * 2012-11-20 2015-03-04 南京工业大学 一种l-鸟氨酸苯乙酸盐的制备方法
CN105481725B (zh) * 2014-09-18 2019-01-22 博瑞生物医药（苏州）股份有限公司 L-精氨酸苯乙酸盐的晶型及其制备方法
CA2968544A1 (en) 2014-11-24 2016-06-02 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
CN113599350A (zh) 2015-04-20 2021-11-05 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐制剂
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
CA2998490A1 (en) * 2015-09-25 2017-03-30 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
JP7294807B2 (ja) * 2015-11-13 2023-06-20 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンフェニルアセテート製剤
US11219611B2 (en) * 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
AU2018266357B2 (en) * 2017-05-11 2022-12-08 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate
CU20200012A7 (es) 2017-08-14 2021-02-04 Axcella Health Inc Composiciones de aminoácidos para el tratamiento de enfermedad hepática
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
SG11202111509PA (en) 2019-05-09 2021-11-29 Ocera Therapeutics Inc Methods of assessing and treating hepatic encephalopathy
CN110707221B (zh) * 2019-09-25 2023-09-01 北京大学深圳研究生院 氨基酸离子液体在制备钙钛矿光电器件中钙钛矿层的应用
US20220362192A1 (en) * 2019-10-16 2022-11-17 Ocera Therapeutics, Inc. Dosages and uses of ornithine phenylacetate for treating hyperammonemia
WO2023240081A1 (en) * 2022-06-06 2023-12-14 Yale University Treatment, amelioration, and/or prevention of inflammatory and autoimmune diseases
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (el) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4100293A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US3950529A (en) * 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4352814A (en) * 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US4857555A (en) 1985-09-12 1989-08-15 Brigham & Women's Hospital Method of treating catabolic dysfunction
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
JP2522034B2 (ja) 1988-12-27 1996-08-07 味の素株式会社 α−ケト酸・アミノ酸塩化合物及びその製造方法
JPH03273578A (ja) 1990-03-23 1991-12-04 Ricoh Co Ltd 対物レンズクリーニング装置
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
DE4020980C1 (el) * 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
JP3166123B2 (ja) 1992-09-09 2001-05-14 フアイソンズ・ピーエルシー 薬剤パッケージング
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US6083953A (en) * 1994-07-28 2000-07-04 Syntex (U.S.A.) Inc. 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
AU2251897A (en) 1996-02-13 1997-09-02 Trustees Of The University Of Pennsylvania, The Method of treating liver disorders
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) * 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
AU4778700A (en) 1999-05-21 2000-12-12 Takeda Chemical Industries Ltd. Liver function controlling agents
US6768024B1 (en) * 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
EP1374863B1 (en) 2001-03-15 2009-09-02 Riken Amino acid compositions for ameliorating liver failure
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20030195255A1 (en) * 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
AU2003261825A1 (en) 2002-08-30 2004-03-19 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
US20050059150A1 (en) * 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) * 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
WO2005082023A2 (en) * 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1744770A2 (en) * 2004-05-06 2007-01-24 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
US20060045912A1 (en) * 2004-08-30 2006-03-02 Peter Truog 4-phenylbutyric acid controlled-release formulations for therapeutic use
SG158073A1 (en) * 2004-11-26 2010-01-29 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
WO2007058634A1 (en) 2005-11-17 2007-05-24 Diagen Smartno Pri Ljubljani, D.O.O. Stable formulation of amorphous perindopril salts, a process for their preparation, especially industrial preparation, and their use in the therapy of hypertension
WO2007077995A1 (ja) 2006-01-05 2007-07-12 Kyowa Hakko Kogyo Co., Ltd. 筋肉増量剤
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
US20090306209A1 (en) 2008-06-04 2009-12-10 Daugherty F Joseph Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
LT2413924T (lt) 2009-04-03 2018-02-12 Ocera Therapeutics, Inc. L-ornitino fenilo acetatas ir jo gavimo būdai
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
MX375116B (es) 2009-06-08 2025-03-06 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
JP2011236160A (ja) 2010-05-11 2011-11-24 Shinshu Univ 非アルコール性肝疾患治療薬
MX360062B (es) 2010-10-06 2018-10-22 Ocera Therapeutics Inc Metodos de elaboracion de fenilacetato de l-ornitina.
DK2922576T3 (en) 2012-11-21 2018-01-15 Horizon Therapeutics Llc PROCEDURES FOR THE ADMINISTRATION AND EVALUATION OF NITROGEN RINSE MEDICINES FOR TREATING HEPATIC ENCYPHALOPATHY
CN103705490B (zh) 2013-10-31 2016-08-17 蚌埠丰原医药科技发展有限公司 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺
CA2968544A1 (en) 2014-11-24 2016-06-02 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
CN113599350A (zh) 2015-04-20 2021-11-05 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐制剂
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
CA2998490A1 (en) 2015-09-25 2017-03-30 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
AU2018266357B2 (en) 2017-05-11 2022-12-08 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate
SG11202111509PA (en) 2019-05-09 2021-11-29 Ocera Therapeutics Inc Methods of assessing and treating hepatic encephalopathy
US20220362192A1 (en) 2019-10-16 2022-11-17 Ocera Therapeutics, Inc. Dosages and uses of ornithine phenylacetate for treating hyperammonemia
US20230201148A1 (en) 2020-05-22 2023-06-29 Ocera Therapeutics, Inc. Uses of ornithine phenylacetate for treating hyperammonemia

Also Published As

Publication number Publication date
EP3686183A1 (en) 2020-07-29
JP6647336B2 (ja) 2020-02-14
US20220162155A1 (en) 2022-05-26
KR101975726B1 (ko) 2019-05-07
KR102123243B1 (ko) 2020-06-17
EA023051B1 (ru) 2016-04-29
CA2998434C (en) 2020-05-12
PT2413924T (pt) 2018-01-04
IL215449A0 (en) 2011-12-29
JP6328737B2 (ja) 2018-05-23
HRP20221232T8 (hr) 2023-02-03
CA2998344A1 (en) 2010-10-07
AU2010232521B2 (en) 2015-07-16
US10173964B2 (en) 2019-01-08
DK3686183T3 (da) 2022-10-03
US20180319736A1 (en) 2018-11-08
US8492439B2 (en) 2013-07-23
NZ595706A (en) 2014-01-31
MX2020009699A (es) 2021-12-17
US8173706B2 (en) 2012-05-08
PT3686183T (pt) 2022-10-03
EP2413924B1 (en) 2017-09-27
US20150251990A1 (en) 2015-09-10
US10550069B2 (en) 2020-02-04
MX356608B (es) 2018-06-06
JP2020100624A (ja) 2020-07-02
KR20200070438A (ko) 2020-06-17
US9034925B2 (en) 2015-05-19
EP3686183B1 (en) 2022-08-03
US11161802B2 (en) 2021-11-02
JP6010154B2 (ja) 2016-10-19
IL263784A (en) 2019-01-31
CA2757373C (en) 2018-05-08
CA3077846A1 (en) 2010-10-07
US9604909B2 (en) 2017-03-28
SG174982A1 (en) 2011-11-28
CN104230730B (zh) 2017-05-24
HUE060371T2 (hu) 2023-02-28
EP2413924A1 (en) 2012-02-08
CA2757373A1 (en) 2010-10-07
SI2413924T1 (en) 2018-01-31
US8785498B2 (en) 2014-07-22
US20120208885A1 (en) 2012-08-16
EA034409B1 (ru) 2020-02-05
SG10202010988WA (en) 2020-12-30
ZA201107189B (en) 2012-12-27
KR20220067001A (ko) 2022-05-24
CN102421432B (zh) 2014-09-17
CN106810464A (zh) 2017-06-09
JP2012522803A (ja) 2012-09-27
KR20190068561A (ko) 2019-06-18
NO2413924T3 (el) 2018-02-24
JP2015145372A (ja) 2015-08-13
KR102217081B1 (ko) 2021-02-18
CA3077846C (en) 2023-08-22
PL3686183T3 (pl) 2022-11-28
CA2998344C (en) 2020-06-02
SG10201406300YA (en) 2015-01-29
EP4101838A1 (en) 2022-12-14
MX388894B (es) 2025-03-20
HK1248558A1 (en) 2018-10-19
US20100280119A1 (en) 2010-11-04
US20180044281A1 (en) 2018-02-15
US20200239406A1 (en) 2020-07-30
NZ708458A (en) 2017-02-24
MX2011010262A (es) 2012-01-25
HRP20171962T1 (hr) 2018-02-09
CN102421432A (zh) 2012-04-18
KR102399540B1 (ko) 2022-05-17
SMT201700601T1 (it) 2018-03-08
JP7086118B2 (ja) 2022-06-17
ES2791524T3 (es) 2020-11-04
CN106810464B (zh) 2019-01-22
HUE035921T2 (en) 2018-05-28
KR20180033313A (ko) 2018-04-02
JP6144488B2 (ja) 2017-06-07
US20130296429A1 (en) 2013-11-07
JP2018138575A (ja) 2018-09-06
LT3686183T (lt) 2022-11-10
JP2022088504A (ja) 2022-06-14
SMT202200395T1 (it) 2022-11-18
PL2413924T3 (pl) 2018-02-28
CN104230730A (zh) 2014-12-24
CA3205755A1 (en) 2010-10-07
MX375111B (es) 2025-03-06
AU2010232521A1 (en) 2011-11-17
NZ619235A (en) 2015-06-26
EP3263100B1 (en) 2020-04-01
US12516015B2 (en) 2026-01-06
KR20210019592A (ko) 2021-02-22
WO2010115055A1 (en) 2010-10-07
JP2017081940A (ja) 2017-05-18
KR20120006039A (ko) 2012-01-17
EP2413924A4 (en) 2013-01-02
EP3263100A1 (en) 2018-01-03
KR101844605B1 (ko) 2018-04-02
EA201171216A1 (ru) 2012-05-30
EA201500650A1 (ru) 2015-10-30
BRPI1013657A2 (pt) 2016-04-26
ES2928586T3 (es) 2022-11-21
IL215449B (en) 2019-01-31
US20140288327A1 (en) 2014-09-25
DK3263100T3 (da) 2020-05-11
CA2998434A1 (en) 2010-10-07
HRP20221232T1 (hr) 2022-12-23
ES2652187T3 (es) 2018-01-31
LT2413924T (lt) 2018-02-12
DK2413924T3 (en) 2017-12-11

Similar Documents

Publication Publication Date Title
CY1119843T1 (el) Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1122123T1 (el) Συνθεσεις λιπιδικου νανοσωματιδιου και μεθοδοι για απελευθερωση mrna
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1120337T1 (el) Θειοοξικες ενωσεις, συνθεσεις και μεθοδοι χρησης
CY1122639T1 (el) Παραγωγα 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου ως ενδιαμεσα στην παρασκευη παραγωγων [(5-αλογονοφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)- αμινο]αλκανοϊκου οξεος
CY1122580T1 (el) Χημικη συνθεση χρησιμη ως ενδιαμεσο για την παρασκευη ενος αναστολεα κατεχολ-ο-μεθυλοτρανσφερασης
CY1122964T1 (el) Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
CY1122218T1 (el) Αλατα και πολυμορφα της 8-φθορο-2-{4-[(μεθυλαμινο)μεθυλο]φαινυλο}-1,3,4,5-τετραϋδρο-6η-αζεπινο[5,4,3-cd]ινδολο-6-ονης
CY1121204T1 (el) Συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη για διαταραχες που προκαλουνται απο την ige
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
CY1116455T1 (el) Υποκατεστημενα 4-αρυλο-1,4-διυδρο-1,6-ναφθυριδιν αμιδια και η χρηση τους
CY1121076T1 (el) Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες
CY1117743T1 (el) Διυποκατεστημενα οκταϋδροπυρρολο [3,4-c]πυρρολια ως ρυθμιστες υποδοχεα ορεξινης
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
CY1119200T1 (el) Νεα παραγωγα βενζιμιδαζολιου ως ερ4 ανταγωνιστες
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
UY33970A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
CY1116797T1 (el) Αναστολεις φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
UY31870A (es) Receptor metabotrópico de glutamato potenciadores 286